Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

21.7%

5 terminated/withdrawn out of 23 trials

Success Rate

76.2%

-10.4% vs industry average

Late-Stage Pipeline

1 trials in Phase 3/4

Results Transparency

31%

5 of 16 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

Phase 1

11(47.8%)

Phase 2

11(47.8%)

Phase 3

1(4.3%)

23Total

Phase 1(11)

Phase 2(11)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials

NCT05900050Phase 2Terminated

Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®

Role: lead

NCT05874414Phase 1Recruiting

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

Role: lead

NCT07694297Phase 2Not Yet Recruiting

Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure

Role: lead

NCT07110441Phase 1Completed

Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers

Role: lead

NCT06987968Phase 2Terminated

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

Role: lead

NCT01694849Phase 2Completed

Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

Role: lead

NCT05368935Phase 1Completed

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

Role: lead

NCT05116826Phase 1Completed

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

Role: lead

NCT02704403Phase 3Terminated

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

Role: lead

NCT03883607Phase 2Terminated

Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)

Role: lead

NCT03953456Phase 2Terminated

Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)

Role: lead

NCT03985969Phase 1Completed

Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin

Role: lead

NCT04171752Phase 1Completed

Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers

Role: lead

NCT03844555Phase 1Completed

Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients

Role: lead

NCT03124108Phase 2Completed

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

Role: lead

NCT03765671Phase 1Completed

Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients

Role: lead

NCT02142127Phase 1Completed

Mass Balance Study of 14C-labelled GFT505 in Healthy Volunteers

Role: lead

NCT02091310Phase 1Completed

Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers

Role: lead

NCT01474161Phase 1Completed

Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505